Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model

• Published in: PloS one 2013-03, Vol.8 (3), p.e58784
• Main Authors: Parthsarathy, Vadivel, Hölscher, Christian
• Format: Article
• Language: English
• Subjects: Age; Age Factors; Alzheimer Disease - metabolism; Alzheimer's disease; Alzheimers disease; Analysis; Animals; Antidiabetics; Biology; Brain; Cell differentiation; Cell Differentiation - drug effects; Cell growth; Cell proliferation; Cell Proliferation - drug effects; Cell Survival - drug effects; Cells (biology); Chronic effects; Diabetes mellitus; Differentiation (biology); Disease Models, Animal; Doublecortin protein; Female; Glucagon-Like Peptide 1 - administration & dosage; Glucagon-Like Peptide 1 - analogs & derivatives; Glucagon-Like Peptide 1 - pharmacology; Inflammation; Insulin; Insulin-like growth factors; Laboratories; Liraglutide; Medicine; Memory; Mice; Nervous system; Neural stem cells; Neurodegeneration; Neurodegenerative diseases; Neurogenesis; Neurogenesis - drug effects; Neurons; Neurons - cytology; Neurons - drug effects; Neurons - metabolism; Neuroprotection; Peptides; Presenilin 1; Progenitor cells; Receptor mechanisms; Receptors; Rodents; Stem cells; Type 2 diabetes
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0058784

Neurogenesis is a life long process, but the rate of cell proliferation and differentiation decreases with age. In Alzheimer's patients, along with age, the presence of Aβ in the brain inhibits this process by reducing stem cell proliferation and cell differentiation. GLP-1 is a growth factor that has neuroprotective properties. GLP1 receptors are present on neuronal progenitor cells, and the GLP-1 analogue liraglutide has been shown to increase cell proliferation in an Alzheimer's disease (AD) mouse model. Here we investigated acute and chronic effects of liraglutide on progenitor cell proliferation, neuroblast differentiation and their subsequent differentiation into neurons in wild type and APP/PS-1 mice at different ages. APP/PS1 and their littermate controls, aged 3, 6, 12, 15 months were injected acutely or chronically with 25 nmol/kg liraglutide. Acute treatment with liraglutide showed an increase in cell proliferation in APP/PS1 mice, but not in controls whereas chronic treatment increased cell proliferation at all ages (BrdU and Ki67 markers). Moreover, numbers of immature neurons (DCX) were increased in both acute and chronic treated animals at all ages. Most newly generated cells differentiated into mature neurons (NeuN marker). A significant increase was observed with chronically treated 6, 12, 15 month APP/PS1 and WT groups. These results demonstrate that liraglutide, which is currently on the market as a treatment for type 2 diabetes (Victoza(TM)), increases neurogenesis, which may have beneficial effects in neurodegenerative disorders like AD.